Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

With that in mind, let's consider two high-yield dividend stocks worth investing in: Pfizer (NYSE: PFE) and Medical ...

a move that was hurting its margins and long-term prospects. An expensive acquisition strategy that saw Pfizer Inc. (NYSE:PFE) spending nearly $70 billion did not go well with the investors.

Damodaran’s insights reflect a cautious view of market prospects heading ... We purchased Pfizer to capture the potential upside from any turnaround following the COVID-induced boom-bust cycle ...

a move that was hurting its margins and long-term prospects. An expensive acquisition strategy that saw Pfizer Inc. (NYSE:PFE) spending nearly $70 billion did not go well with the investors.

Pfizer has been no stranger to acquisitions in recent years as a way to bolster its growth prospects. Its $43 billion acquisition of oncology company Seagen in 2023 showed it wasn't shying away ...

In this particular instance, the bears have arguably overshot their target, ignoring Pfizer's newer growth prospects, especially on the oncology front. The stock's forward-looking dividend yield ...

Considering the analyst consensus, Pfizer's shares are currently trading below the consensus price target, suggesting some skepticism about near-term growth prospects. The positive news of the ...

Meade talked about the prospects for the industry as the UK and ... “For people like Moderna, Pfizer, J&J and AstraZeneca, Q1 has been fantastic. And I think what they have done has been great ...